Cytochrome P450 isoforms involved in metabolism of the enantiomers of verapamil and norverapamil

British Journal of Clinical Pharmacology

Volumn 47, Issue 5, 1999, Pages 545-552

  Tracy, Timothy S ^a,e   Korzekwa, Kenneth R ^b   Gonzalez, Frank J ^c,d   Wainer, Irving W ^a  

^a WEST VIRGINIA UNIVERSITY   (United States)

^b UNIVERSITY OF PITTSBURGH   (United States)

^c NATIONAL CANCER INSTITUTE   (United States)

^d MCGILL UNIVERSITY   (Canada)

^e GEORGETOWN UNIVERSITY   (United States)

Author keywords

Cytochrome P450; Enantiomer; Metabolism; Norverapamil; Verapamil

Indexed keywords

COMPLEMENTARY DNA; CYTOCHROME P450; NORVERAPAMIL; VERAPAMIL;

ARTICLE; CONTROLLED STUDY; DRUG METABOLISM; ENANTIOMER; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; LYMPHOBLAST; MICHAELIS CONSTANT; PRIORITY JOURNAL;

CELL LINE; CYTOCHROME P-450 CYP2D6; CYTOCHROME P-450 CYP2E1; CYTOCHROME P-450 ENZYME SYSTEM; HUMANS; ISOENZYMES; KINETICS; MIXED FUNCTION OXYGENASES; NITRILES; STEREOISOMERISM; SUBSTRATE SPECIFICITY; TUMOR CELLS, CULTURED; VERAPAMIL;

EID: 0032897280     PISSN: 03065251     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2125.1999.00923.x     Document Type: Article

References (19)

1. Eichelbaum M, Ende M, Remberg G, Schomerus M, Dengler H. The metabolism of DL-[14C]-verapamil in man. Dnig Metab Dispos 1979; 7: 145-148.
2. Vogelgesang D, Echizcn H, Schmidt E, Eichelbaum M. Stereoselectivc first-pass metabolism of highly cleared drugs: studies of the bioavailability of L- and D-verapamil examined with a stable isotope technique. BrJ Clin Pharmacol 1984; 18: 733-740.
3. Kroemer HK, Gautier JC, Beaune P, Henderson C, Wolf CR, Eichelbaum M. Identification of P450 enzymes involved in metabolism of vcrapamil in humans. NaunynSchmiedebergs Arch Pharmacol 1993; 348: 332-337.
4. Busse D, Cosme J, Beaune P, Kroemer HK, Eichelbaum M. Cytochromes of the P450, 2C subfamily are the major enzymes involved in the O-demethylation of verapamil in humans. Naunyn-Sclimicdcbcrgs Arch Pharmacol 1995; 353: 116-121.
5. Gonzalez FJ, Aoyama T, Gelboin HV. Expression of mammalian cytochromc P450 using vaccinia virus. Methods Enzymol 1991; 206: 85-92.
6. Omura T, Sato R. The carbon monoxide-binding pigment of liver microsomcs. I. Evidence for its hemoprotcin nature. J Biol Chcm 1964; 239: 2370-2378.
7. Eichelbaum M, Birkel P, Grube E, Gutgemann U, Somogyi A. Effects of verapamil on P-R intervals in relation to verapamil plasma levels following single i.v. & oral administration and during chronic treatment. Klin Wochenschr 1980; 58: 925-929.
8. Wrighton SA, Brian WR, Sari MA, et al Studies on the expression and metabolic capabilities of human liver cytochrome P450IIIA5 (HLp3). Mol Pharmacol 1990; 38: 207-213.
9. Heben MF, Roberts JP, Prueksaritanont T, Benet LZ. Bioavailability of cyclosporine with concomitant rifampin administration is markedly less than predicted by hepatic enzyme induction. Clin Pharmacol Ther 1992; 52: 453-457.
10. Kolars JC, Awni WM, Merion RM, Watkins PB. First-pass metabolism of cyclosporin by the gut. Lancet 1991; 338: 1488-1490.
11. Lown KS, Kolars JC, Thummel KE, et al Interpatient heterogeneity in expression of CYP3A4 and CYP3A5 in small bowel. Lack of prediction by the erythromycin breath test. Drug Metal Dispos 1994; 22: 947-955.
12. Fromm MF, Busse D, Kroemer HK, Eichelbaum M. Differential induction of prehepatic and hepatic metabolism of verapamil by rifampin. Hepatology 1996; 24: 796-801.
13. Lampen A, Christians U, Guengerich FP, et al. Metabolism of the immunosuppressant tacrolimus in the small intestine: Cytochrome P450, drug interactions, and interindividual variability. Drug Metab Dispos 1995; 23: 1315-1324.
14. Kantola T, Kivisto KT, Neuvoncn PJ. Erythromycin and verapamil considerably increase serum simvastatin and sinwastatin acid concentrations. Clin Pharmacol Tlicr 1998; 64: 177-182.
15. Shimada T, Yamazaki H, Mimura M, Inui Y, Guengerich FP. Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: Studies with liver microsomes of 30 Japanese and 30 Caucasians. J Pliannacol Exp Tlicr 1994; 270: 414-423.
16. Fuhr U, Woodcock BG, Sicwert M. Verapamil and drug mctabolis by the cytochrome P450 isoforms CYP1A2. Ear J Clin Phannacol 1992; 42: 463-464.
17. Mautz DS, Nelson WL, Shen DD. Regioselective and stereoselective oxidation of metoprolol and bufuralol catalyzed by microsomes containing cDNA-expressed human P4502D6. Dni? Metab Dispos 1995; 23: 513-517.
18. Kobayashi S, Murray S, Watson D, Sesardic D, Davies DS, Boobis AR. The specificity of inhibition of debrisoquine 4-hydroxylase activity by quinidine and quinine in the rat is the inverse ofthat in man. Bioclicm Pliannacol 1989; 38: 2795-2799.
19. Krocmer HK, Echizen H, Hcidemann H, Eichelbaum M. Predictability of the in vivo metabolism of verapamil from in vitro data: Contribution of individual metabolic pathways and stereoselective aspects. J Pharmacol Exp Tlicr 1992; 260: 1052-1057.